Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 3, 2003

View Archived Issues

NeuGene antisense drugs make progress in infectious disease program

Genzyme and MacroGenics collaborate on therapies for immune-mediated disease

Tripep identifies new candidate drug for HIV

Good gastrointestinal safety profile reported for licofelone in osteoarthritis patients

MMF as effective as i.v. cyclophosphamide in severe lupus nephritis

Doxycycline associated with benefits in osteoarthritis of the knee, rheumatoid arthritis

Absence of causal relationship reported for lymphoma and anti-TNF-alpha drugs

Potential therapeutic effects of atorvastatin in rheumatoid arthritis

Improved organ function and reduced mortality described for drotrecogin alfa (activated) in sepsis

Abbott claims new Bcl-XL/Bcl-2 inhibitors and their use in cancer therapy

New nitrooxy-containing probucol analogues recently patented by NicOx

Novel NPY antagonists prepared and tested at Banyu

GSK presents new inhibitors of Msk-1 and/or Rho kinases

New adamantane-based P2X7 antagonists under study at AstraZeneca

Antitumor fredericamycin analogues developed at Biofrontera

AstraZeneca scientists identify novel chemokine CCR5 modulators

New antihistaminic agents in early development at Sun Pharmaceutical

Synagis approved for expanded use in Europe

Risperdal Consta receives FDA approval

Seroquel deemed approvable by the FDA

Actimid enters phase II trial for prostate cancer

Chiron to initiate phase III tifacogin study in severe community-acquired pneumonia

Celltech gains European rights to Xyrem

Pfizer submits sNDA for Geodon for acute bipolar mania

TC-1734 successfully completes two phase I studies

Potent antiinflammatory effects described for new p38 kinase inhibitor

New triazoles from Meiji Seika exert in vitro and in vivo antifungal activity

FLG retains high efficacy against mutant HBV

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...